91 related articles for article (PubMed ID: 14647510)
1. Inhibition of platelet thromboxane receptor function by a thrombin receptor-targeted pepducin.
Stampfuss JJ; Schrör K; Weber AA
Nat Med; 2003 Dec; 9(12):1447; author reply 1447-8. PubMed ID: 14647510
[No Abstract] [Full Text] [Related]
2. Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1).
Nantermet PG; Barrow JC; Lundell GF; Pellicore JM; Rittle KE; Young M; Freidinger RM; Connolly TM; Condra C; Karczewski J; Bednar RA; Gaul SL; Gould RJ; Prendergast K; Selnick HG
Bioorg Med Chem Lett; 2002 Feb; 12(3):319-23. PubMed ID: 11814787
[TBL] [Abstract][Full Text] [Related]
3. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
4. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets.
Henriksen RA; Hanks VK
Arterioscler Thromb Vasc Biol; 2002 May; 22(5):861-6. PubMed ID: 12006403
[TBL] [Abstract][Full Text] [Related]
5. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis.
Aoki T; Tomiyama Y; Honda S; Senzaki K; Tanaka A; Okubo M; Takahashi F; Takasugi H; Seki J
Thromb Haemost; 1998 Jun; 79(6):1184-90. PubMed ID: 9657446
[TBL] [Abstract][Full Text] [Related]
6. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
8. G-protein-coupled receptors as signaling targets for antiplatelet therapy.
Smyth SS; Woulfe DS; Weitz JI; Gachet C; Conley PB; Goodman SG; Roe MT; Kuliopulos A; Moliterno DJ; French PA; Steinhubl SR; Becker RC;
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):449-57. PubMed ID: 19023091
[TBL] [Abstract][Full Text] [Related]
9. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation.
Covic L; Misra M; Badar J; Singh C; Kuliopulos A
Nat Med; 2002 Oct; 8(10):1161-5. PubMed ID: 12357249
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
11. Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles.
Temple KJ; Duvernay MT; Maeng JG; Blobaum AL; Stauffer SR; Hamm HE; Lindsley CW
Bioorg Med Chem Lett; 2016 Nov; 26(22):5481-5486. PubMed ID: 27777004
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of proteinase-activated receptor agonists on human platelets.
Chung AW; Jurasz P; Hollenberg MD; Radomski MW
Br J Pharmacol; 2002 Mar; 135(5):1123-32. PubMed ID: 11877318
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
Tubaro E; Belogi L; Mezzadri CM
Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
[TBL] [Abstract][Full Text] [Related]
14. Shifts in the affinity distribution of one class of seven-transmembrane receptors by activation of a separate class of seven-transmembrane receptors.
Djellas Y; Antonakis K; Le Breton GC
Biochem Pharmacol; 2000 Jun; 59(12):1521-9. PubMed ID: 10799648
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition.
Chłopicki S; Koda M; Chabielska E; Buczko W; Gryglewski RJ
J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):715-22. PubMed ID: 11192944
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
Hornby EJ; Foster MR; McCabe PJ; Stratton LE
Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
[TBL] [Abstract][Full Text] [Related]
17. Interaction of the protein C activation peptide with platelets.
Martínez-Cruz R; Canseco Mdel S; Lopez-Martínez J; Cruz PA; Pérez-Campos E; Cruz MM; Alva FC; Majluf-Cruz A; Zenteno E; Ruiz-Argüelles A
Prep Biochem Biotechnol; 2007; 37(2):139-47. PubMed ID: 17454824
[TBL] [Abstract][Full Text] [Related]
18. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
